期刊文献+

选择性PPARγ调节剂治疗糖尿病的研究新进展 被引量:11

The update research on selective PPARγ modulator in anti-diabetic treatment
下载PDF
导出
摘要 过氧化物酶体增殖物激活受体γ是一类主要调控糖脂代谢与脂肪细胞分化的核受体,与肥胖、胰岛素抵抗和糖尿病的发生发展密切相关,其激动剂作为胰岛素增敏剂治疗2型糖尿病也被临床广泛应用。近年来,随着对PPARγ信号通路和胰岛素增敏剂的深入研究,使我们对选择性PPARγ调节剂类胰岛素增敏剂的认识不断完善和更新。该文主要阐述选择性PPARγ调节剂类胰岛素增敏剂的作用机制和药物研究的最新进展。 PPARγ is a kind of nuclear receptors responsible for the regulation of glucose and lipid metabolisim and adipocyte difference, which is related with the pathogenesis of obesity, insulin resistance and type 2 diabetes mellitus. PPARγagonists as insulin sensitizer have been used in the clinical treatment for type 2 diabetes for more than decades. Recently, with the further research plunging into the PPAR signaling pathway and insulin sensitizer, the recognition of this crucial nuclear receptor has been renewed and developed. The aim of this review is to report the update research outcomes.
作者 环奕 申竹芳
出处 《中国药理学通报》 CAS CSCD 北大核心 2008年第2期149-152,共4页 Chinese Pharmacological Bulletin
基金 国家自然科学基金资助项目(No30371672) 北京市自然科学基金资助项目(No7042042)
关键词 选择性PPARγ调节剂 过氧化物酶体增殖物激活受体Γ 胰岛素增敏剂 糖尿病 selective PPARγ modulator peruxisome proliferators activated receptor γ insulin sensitizer diabetes
  • 相关文献

参考文献21

  • 1Mukherjee R, Hoener P A, Jow L, et al. A selective peroxisome proliferator-activated receptor-gamma(PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes[ J]. Mol Endocrinol,2000,14(9) :1425-33.
  • 2Nissen S E ,Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[ J ]. N Engl J Med,2007,356 (24) :2457-71.
  • 3Miles P D, Barak Y, He W, et al. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency [ J ]. J Clin Invest, 2000,105 ( 3 ) :287-92.
  • 4Laplante M, Sell H, MacNaul K L,et al. PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity:mechanisms for modulation of postprandial lipemia and differential adipose accretion [ J ]. Diabetes, 2003,52 (2) :291-9.
  • 5Boden G, Cheung P, Mozzoli M,et al. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes [ J ]. Metabolism,2003,52:753-9.
  • 6Despres J P, Lemieux I. Abdominal obesity and metabolic syndrome [J]. Nature,2006,444(7121 ) :881-7.
  • 7Long Y C, Zierath J R. AMP-activated protein kinase signaling in metabolic regulation [ J ]. J Clin Invest ,2006,116 (7) : 1776-83.
  • 8Ekins S, Schuetz E. The PXR crystal structure: the end of the beginning[ J ]. Trends Pharmacol Sci,2002,23 (2) :49-50.
  • 9Guo L, Zhang L, Sun Y, et al. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells [ J ]. Mol Divers, 2006,10(3) :349-60.
  • 10Liu K G, Smith J S, Ayscue A H, et al. Identification of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids with activity on PPARalpha, PPARgamma, and PPARdeha [ J ]. Bioorg Med Chem Lett ,2001,11 ( 17 ) :2385-8.

二级参考文献25

  • 1任先达,吕艳青,叶开和,蔡绍晖,叶春玲.非甾体类抗炎药抗肿瘤作用的分子机制[J].中国药理学通报,2005,21(5):527-531. 被引量:14
  • 2Vosper H,Khoudoli G,Graham T,Palmer C.Peroxisome proliferator-activated receptor agonists,hyperlipidaemia,and atherosclerosis[J].Pharmacol Ther,2002,95(1):47-62.
  • 3Hihi A K,Michalik L,Wahli W.PPARs:transcriptional effectors of fatty acids and their derivatives[J].CMLS,2002,59(5):790-8.
  • 4Wahli W.Peroxisome proliferator-activated receptors (PPARs):from metabolic control to epidermal wound healing[J].Swiss Med Wkly,2002,132(7-8):83-91.
  • 5Peters J M,Lee S S T,Li W,et al.Growth,adipose,brain,and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptorβ/δ[J].Mol Cell Biol,2000,20(14):5119-28.
  • 6Di P N,Michalik L,Tan N S,et al.The anti-apoptotic role of PPARβ contributes to efficient skin wound healing[J].J Steroid Biochem Mol Biol,2003,85(2-5):257-65.
  • 7Leibowitz M D,Fievet C,Hennuyer N,et al.Activation of PPARδ alters lipid metabolism in db/db mice[J].FEBS Letters,2000,473(3):333-6.
  • 8Wang Y X,Lee C H,Tiep S,et al.Peroxisome proliferator-activated receptor δ activates fat metabolism to prevent obesity[J].Cell,2003,113(2):159-70.
  • 9Toshiya T,Joji Y,Satoshi I,et al.Activation of peroxisome proliferator-activated receptor δ induces fatty acid δ-oxidation in skeletal muscle and attenuates metabolic syndrome[J].PNAS,2003,100(26):15924-9.
  • 10Uwe D,Tamara L A,Jyotsna B P,et al.The peroxisome proliferators-activated receptor β/δ agonist,GW501516,regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells[J].Mol Endocrinol,2003,17(12):2477-93.

共引文献10

同被引文献159

引证文献11

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部